In August 2022, Partner Lee Rosebush updated “Due Diligence in Drug Compounding M&A Deals,” published as a LexisNexis Practical Guidance article and originally written with Associate Marc Wagner. The article addresses regulatory risk reduction in mergers and acquisitions between compounding pharmacies and focuses particular attention on Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act (FDCA).